Closely-held PharmaJet’s needle-free injection system will be used to deliver a SARS-CoV mRNA vaccine being developed by Abnova, the world’s largest antibody vaccine manufacturer.
“Our system has been found to improve the immune response of multiple RNA/DNA vaccines, in addition to its proven ease of administration in wide-scale immunization settings,” Chris Cappello, PharmaJet’s president and CEO, said in a statement.
Dr. Wilber Huang, Abnova’s president and CEO, said, “We have taken a major next step toward mRNA vaccine development against COVID-19 based on the specific gene sequences generating successful antibody response from our DNAx immune platform. We would like to complement the mRNA immunization with a needle-free platform to further augment the protective antibody response against COVID-19 with an impactful clinical outcome.”
